Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2

Nature Communications

Volumn 6, Issue , 2015, Pages

  Oberthür, Dominik ^a,b   Achenbach, John ^c   Gabdulkhakov, Azat ^d   Buchner, Klaus ^c   Maasch, Christian ^c   Falke, Sven ^a   Rehders, Dirk ^a   Klussmann, Sven ^c   Betzel, Christian ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b DESY   (Germany)

^c NOXXON PHARMA AG   (Germany)

^d INSTITUTE OF PROTEIN RESEARCH   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DIHYDROLIPOAMIDE DEHYDROGENASE; EMAPTICAP PEGOL; EOTAXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; RNA; SELENIUM; NOX-E36 APTAMER; RECOMBINANT PROTEIN;

CHEMICAL BINDING; CRYSTAL STRUCTURE; MOLECULAR ANALYSIS; PROTEIN; RNA;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DIABETIC NEPHROPATHY; DRUG EFFICACY; HUMAN; MOLECULAR INTERACTION; MONOCYTE; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION; CHEMISTRY; ESCHERICHIA COLI; METABOLISM; MOLECULAR MODEL; X RAY CRYSTALLOGRAPHY;

APTAMERS, NUCLEOTIDE; CHEMOKINE CCL2; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI; HUMANS; MODELS, MOLECULAR; RECOMBINANT PROTEINS;

EID: 84928789604     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7923     Document Type: Article

References (60)

1. Baggiolini, M., Dewald, B. & Moser, B. Human chemokines: an update. Annu. Rev. Immunol. 15, 675-705 (1997).
2. Allen, S. J., Crown, S. E. & Handel, T. M. Chemokine: receptor structure, interactions, and antagonism. Annu. Rev. Immunol. 25, 787-820 (2007).
3. Wang, X., Sharp, J. S., Handel, T. M. & Prestegard, J. H. Chemokine oligomerization in cell signaling and migration. Prog. Mol. Biol. Transl. Sci. 117, 531-578 (2013).
4. Proudfoot, A. E. et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl Acad. Sci. USA 100, 1885-1890 (2003).
5. Dawson, J., Miltz, W., Mir, A. K. & Wiessner, C. Targeting monocyte chemoattractant protein-1 signalling in disease. Expert. Opin. Ther. Targets 7, 35-48 (2003).
6. Gerard, C. & Rollins, B. J. Chemokines and disease. Nat. Immunol. 2, 108-115 (2001).
7. Yadav, A., Saini, V. & Arora, S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin. Chim. Acta 411, 1570-1579 (2010).
8. Eulberg, D., Purschke, W., Anders, H.-J., Selve, N. & Klussmann, S. Spiegelmer NOX-E36 for renal diseases. in Therapeutic Oligonucleotides (ed. Kurreck, J.) 200-225 (Royal Society of Chemistry, 2008).
9. Eulberg, D., Jarosch, F., Vonhoff, S. & Klussmann, S. Spiegelmers for therapeutic applications - use of chiral principles in evolutionary selection techniques. in The Aptamer Handbook (ed. Klussmann, S.) 417-442 (Wiley-VCH, Weinheim, 2006).
10. Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510 (1990).
11. Baeck, C. et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61, 416-426 (2012).
12. Kulkarni, O. et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J. Am. Soc. Nephrol. 18, 2350-2358 (2007).
13. Ninichuk, V. et al. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am. J. Pathol. 172, 628-637 (2008).
14. Haller, H. G., Baumann, M. & Eulberg, D. CCL2 Inhibition with Emapticap Pegol (NOX-E36) in Type 2 Diabetic Patients with Albuminuria. in 51st ERA-EDTA Congress (Amsterdam, 2014).
15. Yatime, L. et al. Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer. Nat. Commun. 6, 6481 (2015).
16. Sheng, J. & Huang, Z. Selenium derivatization of nucleic acids for phase and structure determination in nucleic acid X-ray crystallography. Int. J. Mol. Sci. 9, 258-271 (2008).
17. Hendrickson, W. A. & Teeter, M. M. Structure of the hydrophobic protein crambin determined directly from the anomalous scattering of sulphur. Nature 290, 107-113 (1981).
18. Lubkowski, J. et al. The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat. Struct. Biol. 4, 64-69 (1997).
19. Handel, T. M. & Domaille, P. J. Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry 35, 6569-6584 (1996).
20. Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415 (2003).
21. Reuter, H., Kamaha, S. & Zerzouf, O. Hydrogen bonds in the crystal structure of strontium hydroxide octahydrate Sr(OH)2 8H2O. Z. Naturforsch. 62b, 215-219 (2007).
22. D'Angelo, P. & Persson, I. Structure of the hydrated and dimethyl sulfoxide solvated rubidium ions in solution. Inorg. Chem. 43, 3543-3549 (2004).
23. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).
24. Zheng, H. et al. Validation of metal-binding sites in macromolecular structures with the CheckMyMetal web server. Nat. Protoc. 9, 156-170 (2014).
25. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007).
26. Hemmerich, S. et al. Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. Biochemistry 38, 13013-13025 (1999).
27. Jarnagin, K. et al. Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2. Biochemistry 38, 16167-16177 (1999).
28. Chakravarty, L., Rogers, L., Quach, T., Breckenridge, S. & Kolattukudy, P. E. Lysine 58 and histidine 66 at the C-terminal a-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding. J. Biol. Chem. 273, 29641-29647 (1998).
29. Lau, E. K. et al. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J. Biol. Chem. 279, 22294-22305 (2004).
30. Blaszczyk, J. et al. Complete crystal structure of monocyte chemotactic protein-2, a CC chemokine that interacts with multiple receptors. Biochemistry 39, 14075-14081 (2000).
31. Crump, M. P., Rajarathnam, K., Kim, K. S., Clark-Lewis, I. & Sykes, B. D. Solution structure of eotaxin, a chemokine that selectively recruits eosinophils in allergic inflammation. J. Biol. Chem. 273, 22471-22479 (1998).
32. Barinka, C., Prahl, A. & Lubkowski, J. Structure of human monocyte chemoattractant protein 4 (MCP-4/CCL13). Acta Crystallogr. D Biol. Crystallogr. 64, 273-278 (2008).
33. Kim, K. S., Rajarathnam, K., Clark-Lewis, I. & Sykes, B. D. Structural characterization of a monomeric chemokine: monocyte chemoattractant protein-3. FEBS Lett. 395, 277-282 (1996).
34. Landgraf, G. et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of the CCL2 antagonist NOX-E36, a novel agent being investigated for treatment of diabetic nephropathy [Abstract]. J. Am. Soc. Nephrol. 23, 960A (2012).
35. Padlan, C. S. et al. An RNA aptamer possessing a novel monovalent cationmediated fold inhibits lysozyme catalysis by inhibiting the binding of long natural substrates. RNA 20, 447-461 (2014).
36. Morozova, N., Allers, J., Myers, J. & Shamoo, Y. Protein-RNA interactions: exploring binding patterns with a three-dimensional superposition analysis of high resolution structures. Bioinformatics 22, 2746-2752 (2006).
37. Rooman, M., Lievin, J., Buisine, E. & Wintjens, R. Cation-pi/H-bond stair motifs at protein-DNA interfaces. J. Mol. Biol. 319, 67-76 (2002).
38. Wintjens, R., Lievin, J., Rooman, M. & Buisine, E. Contribution of cation-pi interactions to the stability of protein-DNA complexes. J. Mol. Biol. 302, 395-410 (2000).
39. Keefe, A. D., Pai, S. & Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537-550 (2010).
40. Obmolova, G. et al. Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888. Mol. Immunol. 51, 227-233 (2012).
41. Reid, C. et al. Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody. Protein Eng. Des. Sel. 19, 317-324 (2006).
42. Pienta, K. J. et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castrationresistant prostate cancer. Invest. New Drugs 31, 760-768 (2013).
43. Sandhu, S. K. et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother. Pharmacol. 71, 1041-1050 (2013).
44. Hoffmann, S., Hoos, J., Klussmann, S. & Vonhoff, S. RNA aptamers and spiegelmers: synthesis, purification, and post-synthetic PEG conjugation. Curr. Protoc. Nucleic Acid Chem. Chapter 4, Unit 4.46.1-30 (2011).
45. Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D 66, 133-144 (2010).
46. Kabsch, W. XDS.. Acta Crystallogr. D 66, 125-132 (2010).
47. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235-242 (2011).
48. Grosse-Kunstleve, R. W. & Adams, P. D. Substructure search procedures for macromolecular structures. Acta Crystallog. D Biol. Crystallogr. 59, 1966-1973 (2003).
49. Terwilliger, T. C. et al. Decision-making in structure solution using Bayesian estimates of map quality: the PHENIX AutoSol wizard. Acta Crystallogr. D Biol. Crystallogr. 65, 582-601 (2009).
50. Murshudov, G. N., Vagin, A. A. & Dodson., E. J. Refinement of Macromolecular Structures by the Maximum-Likelihood method. Acta Cryst. D 53, 1285-1294 (1997).
51. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367 (2011).
52. Harding, M. M. Geometry of metal-ligand interactions in proteins. Acta Crystallogr. D Biol. Crystallogr. 57, 401-411 (2001).
53. Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352-367 (2012).
54. Zheng, H., Chruszcz, M., Lasota, P., Lebioda, L. & Minor, W. Data mining of metal ion environments present in protein structures. J. Inorg. Biochem. 102, 1765-1776 (2008).
55. Allen, F. H. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr.B Struct. Sci. 58, 380-388 (2002).
56. Auffinger, P., Grover, N. & Westhof, E. Metal ion binding to RNA. Metal Ion Life Sci. 9, 1-35 (2011).
57. Schrodinger, L. L. C. The PyMOL Molecular Graphics System, Version 1.3r1 (2010).
58. Pettersen, E. F. et al. Chimera - A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
59. Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model 51, 2778-2786 (2011).
60. Lu, X. J. & Olson, W. K. 3DNA: a versatile, integrated software system for the analysis, rebuilding and visualization of three-dimensional nucleic-acid structures. Nat. Protoc. 3, 1213-1227 (2008).